| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7208489 | PFIZER | 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones |
Jan, 2023
(1 year, 3 months ago) | |
| US6936612 | PFIZER | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
Jan, 2023
(1 year, 3 months ago) | |
| USRE47739 | PFIZER | 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones |
Mar, 2027
(2 years from now) | |
| US10723730 | PFIZER | Solid forms of a selective CDK4/6 inhibitor |
Feb, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7456168 | PFIZER | 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones |
Jan, 2023
(1 year, 3 months ago) | |
| US11065250 | PFIZER | Solid dosage forms of palbociclib |
Aug, 2036
(12 years from now) | |
Ibrance is owned by Pfizer.
Ibrance contains Palbociclib.
Ibrance has a total of 6 drug patents out of which 3 drug patents have expired.
Expired drug patents of Ibrance are:
- US7456168
- US7208489
- US6936612
Ibrance was authorised for market use on 03 February, 2015.
Ibrance is available in tablet;oral dosage forms.
Ibrance can be used as palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor in pts as initial endocrine-based therapy or with fulvestrant with disease progression after endocrine therapy.
Drug patent challenges can be filed against Ibrance from 03 February, 2019.
The generics of Ibrance are possible to be released after 19 August, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-725) | Feb 19, 2019 |
| New Chemical Entity Exclusivity(NCE) | Feb 03, 2020 |
Drugs and Companies using PALBOCICLIB ingredient
NCE-1 date: 03 February, 2019
Market Authorisation Date: 03 February, 2015
Treatment: Palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor in pts as initial endocrine-based therapy or with fulvestrant with disease progression after...
Dosage: TABLET;ORAL
IBRANCE family patents
